Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: Distribution characteristics in a normal population and cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 4, 2007, Pages 789-795

  Wang, Hui ^a,b   Li, Mao ^a   Lin, Wenyao ^d   Wang, Wenquan ^a   Zhang, Zhuo ^a   Rayburn, Elizabeth R ^a   Lu, Jian ^e   Chen, Deng ^a   Yue, Xinsen ^d   Shen, Fuming ^c   Jiang, Feng ^c   He, Jie ^a,f   Wei, Wu ^g   Zeng, Xiaofei ^a,h   Zhang, Ruiwen ^a,i  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d Haimen Municipal Center for Disease Control and Prevention   (China)

^e Third People's Hospital of Nantong   (China)

^f CANCER HOSPITAL   (China)

^g CHANGZHI MEDICAL COLLEGE   (China)

^h LIAONING UNIVERSITY   (China)

ⁱ University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC AMP DEPENDENT PROTEIN KINASE; LACTATE DEHYDROGENASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CHINESE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; FEMALE; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOASSAY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247500414     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0367     Document Type: Article

References (51)

1. Beebe SJ, Corbin JD. Cyclic nucleotide-dependent protein kinases. In: Boyer PD, Kerbes EG, editors. The enzymes: control by phosphorylation. New York: Academic; 1986. Vol. 17. p. 43-111.
2. Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol 1995;21:33-61.
3. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004;145:5452-8.
4. Cho-Chung YS. cAMP signaling in cancer genesis and treatment. Cancer Treat Res 2003;115:123-43.
5. Matyakhina L, Lenherr SM, Stratakis CA. Protein kinase A and chromosomal stability. Ann N Y Acad Sci 2002;968:148-57.
6. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 2004;11:265-80.
7. Cho YS, Park YG, Lee YN, et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Cα and RIIβ subunit overexpression. Proc Natl Acad Sci U S A 2000;97:835-40.
8. Uhler MD, Carmichael DF, Lee DC, Chivia JC, Krebs EG, McKnight GS. Isolation of cDNA clones coding for the catalytic subunit of mouse cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1986;83:1300-4.
9. Uhler MD, Chrivia JC, McKnight GS. Evidence for a second isoform of the catalytic subunit of cAMP-dependent protein kinase. J Biol Chem 1986;261: 15360-3.
10. Beebe SJ, Oyen O, Sandberg M, Froysa A, Hansson V, Jahnsen T. Molecular cloning of a tissue-specific protein kinase (Cγ) from human testis - representing a third isoform for the catalytic subunit of cAMP-dependent protein kinase. Mol Endocrinol 1990;4:465-75.
11. Levy FO, Oyen O, Sandberg M, et al. Molecular cloning, complementary deoxyribonucleic acid structure and predicted full-length amino acid sequence of the hormone-inducible regulatory subunit of 3′-5′ - cyclic adenosine monophosphate-dependent protein kinase from human testis. MoI Endocrinol 1988;2:1364-73.
12. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional related diseases. Pharmacol Ther 1993;60:265-88.
13. McDaid HM, Cairns MT, Atkinson RJ, et al. Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999;79:933-9.
14. Cvijic ME, Chin KV. Effects of RIα overexpression on cisplatin sensitivity in human ovarian carcinoma cells. Biochem Biophys Res Commun 1998;249: 723-7.
15. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994;69:738-42.
16. Miller WR, Hulme MJ, Bartlett JM, MacCallum J, Dixon JM. Changes in messenger RNA expression of protein kinase A regulatory subunit Iα in breast cancer patients treated with tamoxifen. Clin Cancer Res 1997;3:2399-404.
17. Young MR, Montpetit M, Lozano Y, et al. Regulation of Lewis lung carcinoma invasion and metastasis by protein kinase A. Int J Cancer 1995;61: 104-9.
18. Yang WL, Iacono L, Tang WM, Chin KV. Novel function of the regulatory subunit of protein kinase A: regulation of cytochrome c oxidase activity and cytochrome c release. Biochemistry 1998;37:14175-80.
19. Abraham I, Chin KV, Gottesman MM, Mayo JK, Sampson KE. Transfection of a mutant regulatory subunit gene of cAMP-dependent protein kinase causes increased drug sensitivity and decreased expression of P-glycoprotein. Exp Cell Res 1990;189:133-41.
20. Rohlff C, Glazer R. Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal 1995;7:431-4.
21. Chin C, Bae JH, Kim MJ, et al. Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp Mol Med 2005;37:608-18.
22. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-100.
23. Miller WR, Hulme MJ, Cho-Chung YS, Elton RA. Types of cyclic AMP binding proteins in human breast cancers. Eur J Cancer 1993;29:989-91.
24. Cho YS, Lee YN, Cho-Chung YS. Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker. Biochem Biophys Res Commun 2002;278:679-84.
25. Weissinger EM, Oettrich K, Evans C, et al. Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. Br J Cancer 2004;91:186-92.
26. Tortora G, Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 2002;968:139-47.
27. Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics 2005;5:173-90.
28. Nesterova MV, Cho-Chung YS. Chemoprevention with protein kinase A RIα antisense in DMBA-mammary carcinogenesis. Ann N Y Acad Sci 2005;1058: 255-64.
29. Nesterova MV, Cho-Chung YS. Antisense protein kinase A RIα inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis. Clin Cancer Res 2004;10:4568-77.
30. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS. Compensatory stabilization of RIIβ protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIα protein. Clin Cancer Res 2000;6:3434-41.
31. Cvijic ME, Chin KV. Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin. Int J Cancer 1997;72:345-50.
32. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 1999;96:13989-94.
33. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RIα subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 2002;21:73-80.
34. Mani S, Goel S, Nesterova M, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci 2003;1002: 252-62.
35. Cho YS, Kim MK, Cheadle C, Neary C, Becker KG, Cho-Chung YS. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc Natl Acad Sci U S A 2001;98:9819-23.
36. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005; 26:281-93.
37. Leonard GD, Low JA, Berman AW, Swain SM. CA 125 elevation in breast cancer: a case report and review of the literature. Breast J 2004;10:146-9.
38. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53.
39. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12.
40. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
41. Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol 2005;203:1-5.
42. Herszenyi L, Plebani M, Carrara P, et al. Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 2000;291:171-87.
43. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997;9:380-7.
44. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15:274-81.
45. Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics 2005;5:141-8.
46. Cheung KL, Robertson FR. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers. Minerva Chir 2003;58:297-303.
47. Mok TS, Yeo W, Yu S, et al. An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal α-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol 2005;23:8041-7.
48. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106:320-8.
49. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
50. Avalable from: http://www.cancer.gov/cancertopics/pdq/screening/ prostate/healthprofessional.
51. Kita T, Goydos J, Reitman E, et al. Extracellular cAMP-dependent protein kinase (ECPKA) in melanoma. Cancer Lett 2004;208:187-91.